Navigation Links
Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
Date:8/29/2007

Potential Earlier Identification of Toxicity, Efficacy for Pharmaceutical

Developers

REDWOOD CITY, Calif., Aug. 29 /PRNewswire/ -- Codexis, Inc., a private biotechnology company and leading developer of clean manufacturing processes, today announced it has licensed important intellectual property from the California Institute of Technology for preparing and identifying drug metabolites (substances produced during drug metabolism). Codexis will incorporate this technology in development of new R&D productivity tools for use by the pharmaceutical industry.

This technology is based on development of a family of diverse variants of bacterial cytochrome P450 enzymes by Frances Arnold, Ph.D., Dick and Barbara Dickinson Professor of Chemical Engineering and Biochemistry, Cal Tech. Dr. Arnold will join the Codexis Industrial Advisory Board.

"This enzyme family can facilitate identification of safer, more efficacious drugs earlier in the drug development process by expediting the production of potential human metabolites of drug candidates," said Peter Seufer-Wasserthal, Ph.D., Vice President and General Manager, Codexis Pharma Services Group. "Additionally, this technology can be used for lead diversification and complements the human cytochrome biocatalyst products and services at BioCatalytics, acquired by Codexis in July."

"Current metabolite identification and synthesis methods are based on classical chemistry methods, which can be slow and cumbersome," he added. "Combining Codexis' leading position as a developer of biocatalytic products and processes for the pharmaceutical industry with the techniques developed by Dr. Arnold will enable us to provide a powerful, efficient new tool set for rapid identification and synthesis of drug metabolites. These new tools could add considerable value in metabolite profiling as well as lead diversification in drug discovery."

Drug metabolites are produced by the
'/>"/>

SOURCE Codexis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. GenTel licenses next generation cancer research
2. Third Wave licenses Innogenetics tech to settle lawsuit
3. WARF licenses patents for new glaucoma drug treatment
4. PKWARE Licenses Technology to Expand SecureZIP Standard
5. Mentor Licenses Botulinum From WARF and Plans Wisconsin Manufacturing Facility
6. Simultaneous Determination of Residues of Approximately 100 Pesticides and Metabolites in Fruit and Vegetables by LC/MS/MS
7. Detection of nitrofurane metabolites in food with HPLC/MS/MS
8. Simultaneously characterizing and quantifying chloramphenicol and its metabolite using LC/MS/MS
9. High sensitivity quantitation of metabolites of nitrofuran antibiotics in animal tissue using LC/MS/MS
10. Analysis of Nitrofurans Metabolites by Positive Ion Electrospray LC/MS/MS
11. Simultaneous Detection of CYP3A4, CYP2D6 and CYP2C9 Metabolites with a Single, Sensitive, LC/MS/MS Method
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... -- China Cord Blood Corporation (NYSE: CO ) ... results for the first quarter of fiscal year 2015 ... the US.  The Company will host ... August 29, 2014 to discuss its financial performance and ... followed by a question and answer session.  Interested parties ...
(Date:8/21/2014)... Gallus BioPharmaceuticals , LLC, ... manufacturing organization (CMO) announced today that it has ... company focused on the development of innovative approaches ... anti-prostate specific membrane antigen (PSMA) monoclonal antibody used ... the agreement the antibody will be produced in ...
(Date:8/20/2014)... of patented university inventions licensed to biotechnology firms ... commercialization. To open these roadblocks, the researchers suggest ... the discovery stage could lead to faster commercialization ... derived from discoveries made in university laboratories and ... during clinical trials, which have a high failure ...
(Date:8/20/2014)... 2014 High performance computing (HPC) ... most complete climate and Earth system model to ... issues. , Eight national laboratories, including Lawrence ... Center for Atmospheric Research, four academic institutions and ... participating national laboratories include Argonne, Brookhaven, Lawrence Berkeley, ...
Breaking Biology Technology:China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3
... is pleased to announce the,never- before assembly of ... Lighting the Onco-Pipeline -- Innovations in Stem Cell,Biomarker, ... in Tampa,Florida. iiBIG is particularly pleased to join ... Florida, University of Florida, Shands,Cancer Center, Scripps Florida, ...
... Ultra-Fine Beam Shaping Device Optimized for Targeting ... Stereotactic Radiotherapy and Radiosurgery, PALO ALTO, ... (NYSE: VAR ) has received FDA ... (MLC), an ultra-fine beam shaping,device for radiosurgery. ...
... Morria Biopharmaceuticals Plc, a,private biopharmaceutical company ... today that it has,appointed Rosemary Mazanet M.D., ... Mazanet has significant experience in both executive ... Dr. Mazanet serves on the Board of ...
Cached Biology Technology:Lighting the Onco-Pipeline, Stem Cell Cancer, and More at Global Cancer Congress, January 28-29, 2008, Tampa 2Lighting the Onco-Pipeline, Stem Cell Cancer, and More at Global Cancer Congress, January 28-29, 2008, Tampa 3Varian Medical Systems Receives FDA 510(k) Clearance for High-Definition Collimator That Enables Ultra-Fine Intensity-Modulated Radiosurgery 2Varian Medical Systems Receives FDA 510(k) Clearance for High-Definition Collimator That Enables Ultra-Fine Intensity-Modulated Radiosurgery 3Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer 2
(Date:8/21/2014)... the pancreas digesting itself resulting in severe abdominal pain, ... around 20,000 patients are diagnosed with the disease resulting ... treatment is restricted to intravenous fluid and nutritional support. ... Life Sciences, who led the research, said "The major ... stones and excessive alcohol intake combined with a high ...
(Date:8/20/2014)... , Aug. 20, 2014 /CNW/ -  Issue ... and can quickly become life threatening for some children.    ... as 1.2 million Canadians have food allergies and this number ... cent of children are estimated to have food allergies.  ... mild skin irritations and hives to breathing difficulties and loss ...
(Date:8/20/2014)... of Health has awarded the Oklahoma Medical Research Foundation ... on anthrax and the bacteria,s effects on humans. ... and his colleagues have studied the human immune response ... for Human Immunology. The original funding came soon after ... heels of the terrorist attacks of Sept. 11, 2001. ...
Breaking Biology News(10 mins):Insulin offers new hope for the treatment of acute pancreatitis 2Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3$14.5 million grant awarded to continue anthrax studies 2
... United States, African Americans have approximately twice the risk ... a similar prevalence in earlier stages of chronic kidney ... (GW) researcher Dominic Raj, M.D., identifies factors that mediate ... black patients and white patients, as well as among ...
... range-wide assessment of the bonobo (formerly known as the ... known and endangered great ape is quickly losing space ... of usable habitat is attributed to both forest fragmentation ... of Georgia, University of Maryland, the Wildlife Conservation Society, ...
... University School of Medicine (BUSM) and Boston Medical Center ... initiative funded by the Bill & Melinda Gates Foundation. ... BMC, and Ducksoo Kim, MD, professor of radiology at ... fellowship at BMC, will use nanotechnology to develop a ...
Cached Biology News:Genetics contribute to increased risk for end-stage renal disease for African Americans with CKD 2Study finds the forgotten ape threatened by human activity and forest loss 2Study finds the forgotten ape threatened by human activity and forest loss 3BUSM/BMC receives Grand Challenges Explorations grant to develop next generation condom 2BUSM/BMC receives Grand Challenges Explorations grant to develop next generation condom 3
... Custom monoclonal antibody development to targets including ... molecules, DNA, and cancer-specific surface antigens. ... and is completed in approximately 40 days ... nature of antigens). Phase I: Immunization, ...
... Clone/PAD: ZMD.460. Immunogen: Synthetic peptide ... human C35 protein (chromosome 17 open reading ... Specific for the C35 protein. On ... at ~15 kDa band. Reactivity: Human ...
... Peptide sequences: Two separate ... corresponding to the same sequence used ... antiserum (Catalog No. 160890) ... with Cayman's guanylate cyclase polyclonal antiserum ...
Immunogen: Secretory component isolated from human colostrum. Storage: 4 C...
Biology Products: